--- title: "ভারতে GLP-1 Therapy-এর জন্য কে Qualify?" description: "India GLP-1 RA eligibility—BMI threshold, comorbidity, thin-fat phenotype, doctor evaluate কী।. Medically reviewed, CDSCO-aware guides for Indian patients.…" canonical: "https://www.kesho.health/bn/blog/who-qualifies-glp-1-india" markdown_url: "https://www.kesho.health/md/bn/blog/who-qualifies-glp-1-india" date_published: "Jun 15, 2026" date_modified: "Jun 26, 2026" author: "Dr. Ananya Mehta" language: "bn-IN" primary_keyword: "GLP-1 eligibility India" --- # ভারতে GLP-1 Therapy-এর জন্য কে Qualify? > **Short answer:** India GLP-1 RA RSSDI first-line insufficient type 2 diabetes; obesity BMI ≥27.5 kg/m² বা prediabetes/hypertension/fatty liver comorbidity-সহ ≥25 ICMR। obesity pharmacotherapy lifestyle trial precedes। contraindication, affordability, monitoring capacity physician assess—Kesho qualification determine/guarantee নয়। specialist visit lab, waist, lifestyle documentation bring। **Canonical HTML:** https://www.kesho.health/bn/blog/who-qualifies-glp-1-india **Markdown:** https://www.kesho.health/md/bn/blog/who-qualifies-glp-1-india *GLP-1 eligibility simple BMI checklist নয়। ICMR RSSDI South Asian earlier metabolic risk thin-fat phenotype, central obesity, young age family diabetes account। criteria doctor use informed consultation prepare, decline why understand, self-diagnose unregulated seller prescription guarantee avoid। documentation honest lifestyle history scale number equally matter। diabetes obesity pathway contraindication screening CDSCO Schedule H nationwide equally apply।* *Reviewed by Dr. Ananya Mehta, MD, DM Endocrinology. This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.* ## Key takeaways - Type 2 diabetes indication high BMI not required—RSSDI metformin lifestyle HbA1c target unmet GLP-1 RA support। - Obesity ICMR-aligned BMI ≥27.5, comorbidity-সহ ≥25—Western BMI ≥30 lower। - Waist (>90 cm men, >80 cm women) thin-fat phenotype South Asian BMI equally matter। - Pregnancy, MTC/MEN2 history, severe pancreatitis contraindication—BMI regardless CDSCO label। - Obesity pharmacotherapy 3–6 month lifestyle intervention precedes; GLP-1 cosmetic shortcut never। ## At a glance (India) | Field | Value | | --- | --- | | Obesity BMI threshold (no comorbidity) | ≥27.5 kg/m² (ICMR-aligned) | | Obesity BMI with comorbidity | ≥25 kg/m² | | Waist risk (South Asian men / women) | >90 cm / >80 cm | | Typical diabetes HbA1c trigger | >7–7.5% despite first-line care | | Lifestyle trial before obesity Rx | Usually 3–6 months | | Prescription requirement | Schedule H; CDSCO-approved products | ## In this article - Type 2 diabetes indications - Obesity and weight criteria - Indian BMI thresholds explained - Comorbidities that matter - Who may not qualify - Assessment workflow - Family history and risk - If you were declined - Self-assessment mistakes - Preparing for your assessment - Sleep apnoea and metabolic syndrome - Prediabetes pathway in India - Employer wellness programmes - Documentation for insurance appeals - Re-evaluation timelines ## Type 2 diabetes-এ GLP-1 therapy qualify? RSSDI GLP-1 RA important option lifestyle metformin glycaemic target fail typically HbA1c 7–7.5% above optimised care। particularly established cardiovascular disease, heart failure, CKD, obesity, sulfonylurea hypoglycaemia risk favour। single BMI cut-off diabetes indication নয়; lean Indian type 2 overall cardiovascular renal risk GLP-1 RA। age kidney concurrent medicine selection influence। type 1 gestational without specialist diabetic ketoacidosis not indicated। diabetologist/endocrinologist HbA1c trend fasting post-meal glucose complication screening class recommend। CDSCO product Schedule H prescription clinical criteria clear equally require। ## India obesity criteria GLP-1? Obesity pharmacotherapy ICMR national guideline South Asia adapted BMI ≥27.5 kg/m² without comorbidity medication consider, BMI ≥25 comorbidity present। Western BMI ≥30 below threshold Indians insulin resistance fatty liver cardiovascular risk lower weight। waist men 90 cm+ women 80 cm+ South Asian BMI supplement clinical assessment। pharmacotherapy never first-line structured lifestyle three-six months follow। motivation mental health eating disorder history long-term therapy afford assess before prescribe। cosmetic motivation metabolic indication appropriate prescribing নয়। BMI threshold structured lifestyle attempt defer dietitian refer first। ### Thin-fat phenotype South Asian common pattern: apparently normal BMI high visceral fat low muscle mass early metabolic disease associate। ## Indian BMI threshold Western guideline differ কেন? Asian Indian phenotype Joshi et al. literature higher visceral adiposity greater insulin resistance earlier type 2 diabetes Caucasian same BMI। Chennai BMI 26 European BMI 28 metabolic risk higher। RSSDI ICMR incorporate realities। clinical judgement essential: marathon vegetarian BMI 27 no comorbidity differ sedentary executive BMI 27 prediabetes fatty liver manage। genetic family history socioeconomic population guideline fully capture individual decision। WHO Asian BMI cut-off underpin ICMR India-specific most directly relevant patient document। ### BMI thresholds: Western vs India-aligned - Context: Pharmacotherapy without comorbidity — Western: Often BMI ≥30 — India-aligned: Often BMI ≥27.5 (ICMR) - Context: Pharmacotherapy with comorbidity — Western: Often BMI ≥27 — India-aligned: Often BMI ≥25 with comorbidity - Context: Waist circumference — Western: Less emphasised — India-aligned: Central obesity central to risk - Context: Lifestyle trial first — Western: Recommended — India-aligned: Required 3–6 months (ICMR) - Context: Type 2 diabetes indication — Western: Glycaemic criteria — India-aligned: RSSDI after metformin if uncontrolled ### Common comorbidity earlier GLP-1 consideration support (BMI ≥25) - Comorbidity: Prediabetes/elevated HbA1c — Why: Diabetes progression reduce; insulin sensitivity improve - Comorbidity: Hypertension — Why: Weight loss glycaemic control BP management support - Comorbidity: Dyslipidaemia — Why: GLP-1 RA triglyceride weight-related lipid improve may - Comorbidity: NAFLD/fatty liver — Why: 5–10% weight loss hepatic steatosis reduce - Comorbidity: Obstructive sleep apnoea — Why: Weight reduction apnoea severity improve many - Comorbidity: Established cardiovascular disease — Why: RSSDI high-risk diabetes GLP-1 RA favour ## Comorbidity GLP-1 therapy case strengthen? BMI beyond metabolic condition cluster weigh। central obesity prediabetes multiple agent hypertension high triglyceride ultrasound NAFLD obstructive sleep apnoea each lifestyle alone insufficient pharmacotherapy justification add। PCOS insulin resistance endocrine discussion frequent। premature cardiovascular disease diabetes family history borderline number risk framing strengthen। RSSDI cardiovascular integration diabetes heart disease GLP-1 RA algorithm earlier isolated mild obesity patient। lab imaging self-report alone document। ICMR obesity chronic disease complication treat cosmetic issue emphasise। ## Qualify না বা specialist review? Contraindication pregnancy breastfeeding MTC/MEN2 severe prior pancreatitis। severe gastroparesis active IBD frail elderly low BMI further weight loss harmful caution। inadequately treated eating disorder psychiatric support before appetite-suppressing medicine। monitoring afford sustained therapy unable alternative counsel। first-degree thyroid cancer history careful endocrine evaluation। Kesho screen eligibility determine নয়—only treating physician full history examination investigation decide। CDSCO product label contraindication BMI regardless legally binding। ## Frequently asked questions ### Do I qualify for GLP-1 if my BMI is 24? BMI alone below 25 rarely supports obesity indication unless significant comorbidities and central obesity exist—waist above South Asian cut-offs may still prompt discussion at 25+ with metabolic risk. Type 2 diabetes indication does not require high BMI; RSSDI supports GLP-1 RAs for uncontrolled glycaemia after first-line therapy. Your doctor assesses the full clinical picture including labs, family history, and prior lifestyle attempts. Document waist circumference, prediabetes labs, and fatty liver imaging if available to strengthen borderline cases. ### Can teenagers get GLP-1 in India? Paediatric obesity management requires specialist care. Some GLP-1 RAs have limited adolescent approvals globally; Indian practice varies. A paediatric endocrinologist must guide any decision. ### Does prediabetes alone qualify me? Prediabetes with BMI ≥25 and other risk factors may support obesity pharmacotherapy discussion after lifestyle trial per ICMR guidance. Lifestyle intervention remains first-line—structured diet and activity records strengthen your case at reassessment. Medication decisions are individualised; prediabetes alone at BMI 23 without comorbidities rarely justifies GLP-1 initiation. ### I have PCOS—am I eligible? PCOS with insulin resistance and elevated BMI often prompts GLP-1 discussion for weight and metabolic benefits. Gynaecologist and endocrinologist collaboration is recommended when fertility goals, contraception, and glucose targets intersect. PCOS alone without meeting BMI or comorbidity thresholds may not justify pharmacotherapy—lifestyle and hormonal management remain foundational per standard Indian practice. ### Can I get GLP-1 only for cosmetic weight loss? Ethical prescribing targets health-related obesity with comorbidity risk, not cosmetic goals alone per ICMR frameworks. Doctors may decline when BMI, waist, and metabolic risk do not meet criteria—even if social pressure or event deadlines create urgency. Pharmacotherapy without medical indication exposes you to unnecessary side effects and cost. Focus on documented health markers and lifestyle records rather than appearance targets alone when discussing eligibility. ### Does a normal HbA1c disqualify me? For diabetes indication, inadequate glycaemic control is usually required—normal HbA1c suggests diabetes-specific indication may not apply unless other factors warrant continued review. For obesity indication, HbA1c may be normal while waist circumference, fatty liver, or prediabetes still support pharmacotherapy discussion per ICMR. Criteria depend on the treatment goal your doctor is addressing; bring full labs, not BMI alone. ### How long must I try lifestyle changes before GLP-1 for obesity? ICMR guidance typically expects structured lifestyle intervention over three to six months before obesity pharmacotherapy, documented with weight, diet, and activity records. Type 2 diabetes pathways may intensify earlier when HbA1c remains above target despite metformin and lifestyle per RSSDI. Your doctor will clarify which pathway applies to your case. ### Does fatty liver alone qualify me for GLP-1? NAFLD strengthens obesity pharmacotherapy discussion when combined with BMI ≥25 and other metabolic risk after lifestyle trial. Fatty liver at BMI below twenty-five without diabetes typically requires individual specialist assessment—not automatic GLP-1 indication. ### Can I qualify if I already take metformin? Metformin use is common and compatible with GLP-1 initiation for type 2 diabetes when HbA1c remains above target. For obesity-only indication, metformin alone does not replace BMI and lifestyle criteria. Bring current metformin dose and glucose response data to your assessment. ### How does hypothyroidism affect GLP-1 eligibility? Hypothyroidism itself is not a contraindication if adequately treated—optimise thyroid hormone replacement before obesity or diabetes pharmacotherapy decisions. Untreated hypothyroidism can elevate weight and lipids, confounding eligibility assessment. Personal or family medullary thyroid carcinoma history is a separate contraindication from common hypothyroidism. Bring recent thyroid labs and medication doses to your specialist visit. ### Can I qualify with normal blood pressure and lipids? Yes for obesity pathway if BMI and lifestyle trial criteria are met—comorbidities strengthen but are not always mandatory at BMI ≥27.5. Diabetes pathway focuses on HbA1c and RSSDI cardiovascular criteria. Bring full metabolic labs, not BMI alone, to specialist assessment. Document prior dietitian or structured programme attendance when available. ## People also ask ### Can I get GLP-1 with BMI 23 if I have fatty liver? BMI alone below 25 rarely supports obesity pharmacotherapy. However, type 2 diabetes or prediabetes pathways may still apply if glycaemic criteria are met. Fatty liver with central obesity and strong metabolic risk may prompt discussion at BMI 25+ with comorbidities. Only your doctor can decide after full workup. ### Do I need a diabetes diagnosis to qualify? Not always. GLP-1 RAs are used for obesity in eligible adults without diabetes when ICMR BMI and comorbidity criteria are met after lifestyle trial. Conversely, type 2 diabetes patients may qualify without high BMI based on RSSDI glycaemic and cardiovascular criteria. ### Will my doctor prescribe GLP-1 for PCOS? PCOS with insulin resistance, elevated BMI, and metabolic risk often leads to GLP-1 discussion. Gynaecologist and endocrinologist collaboration is recommended. PCOS alone without meeting weight or glucose criteria may not justify pharmacotherapy. ### Can I qualify if I am prediabetic only? Prediabetes with BMI ≥25 and additional risk factors may support obesity pharmacotherapy discussion per ICMR frameworks. Lifestyle intervention remains first-line. Medication is individualised—not automatic for prediabetes alone. ### Does age affect GLP-1 eligibility in India? Adults are the primary population in CDSCO-approved labelling. Elderly frail patients with low BMI may be poor candidates due to unintended weight loss. Paediatric use requires specialist paediatric endocrinology—never adult telehealth shortcuts. ### What if my HbA1c is already normal? For obesity indication, normal HbA1c does not disqualify you if BMI and comorbidity criteria are met. For diabetes indication, inadequate glycaemic control is typically required—normal HbA1c suggests diabetes indication may not apply. ### Can corporate wellness programmes guarantee GLP-1 access? No ethical programme guarantees prescriptions. Eligibility requires medical evaluation, contraindication screening, and often documentation of prior lifestyle attempts for obesity indications. Avoid platforms promising automatic approval. ### How does kidney disease affect qualification? Mild to moderate kidney disease does not automatically exclude GLP-1 RAs and may favour them in diabetes with CKD per RSSDI. Severe renal impairment requires specialist dosing review. Bring recent creatinine and eGFR results to your appointment. ### I had bariatric surgery—can I still use GLP-1? Some post-bariatric patients with weight regain or recurrent diabetes may be candidates, but anatomy, nutrition status, and surgical history require multidisciplinary assessment. This is specialist territory—not self-requested prescribing. ### What documents speed up eligibility review? Bring recent HbA1c, fasting glucose, lipid panel, liver and kidney tests, thyroid history, weight trend records, prior diet programme documentation, medication list including supplements, and family history of thyroid cancer or pancreatitis. ### Does waist size alone qualify me for GLP-1? Waist above South Asian cut-offs (>90 cm men, >80 cm women) supports metabolic risk assessment alongside BMI but rarely qualifies alone without comorbidities or meeting ICMR BMI thresholds. Doctors integrate waist, labs, and history—not single measurements. ### Can I qualify with normal blood pressure and lipids? Yes for obesity pathway if BMI and lifestyle trial criteria are met—comorbidities strengthen but are not always mandatory at BMI ≥27.5. Diabetes pathway focuses on HbA1c and RSSDI cardiovascular criteria rather than requiring every comorbidity. ## References 1. [ICMR Expert Group. (2024). National Guidelines for Obesity Management in India.](https://www.icmr.gov.in/) 2. [RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus (2023).](https://rssdi.in/) 3. [Joshi SR, et al. (2012). The Asian Indian Phenotype. JAPI, 60(Suppl), 5-8.](https://pubmed.ncbi.nlm.nih.gov/23165626/) 4. [WHO Expert Consultation. (2004). Appropriate BMI for Asian Populations.](https://pubmed.ncbi.nlm.nih.gov/14749299/) 5. [CDSCO. Drug Alerts and Advisories on GLP-1 Receptor Agonists.](https://cdsco.gov.in/) ## Related guides - [glp-1-explained-india](https://www.kesho.health/blog/glp-1-explained-india) · [MD](https://www.kesho.health/md/blog/glp-1-explained-india) - [how-to-talk-to-doctor-glp-1-india](https://www.kesho.health/blog/how-to-talk-to-doctor-glp-1-india) · [MD](https://www.kesho.health/md/blog/how-to-talk-to-doctor-glp-1-india) - [semaglutide-india-complete-guide](https://www.kesho.health/blog/semaglutide-india-complete-guide) · [MD](https://www.kesho.health/md/blog/semaglutide-india-complete-guide) - [glp-1-vs-bariatric-surgery-india](https://www.kesho.health/blog/glp-1-vs-bariatric-surgery-india) · [MD](https://www.kesho.health/md/blog/glp-1-vs-bariatric-surgery-india) --- *Kesho provides GLP-1 education only. We do not prescribe or sell medications. [Editorial policy](https://www.kesho.health/editorial-policy).*